NCT06457334

Brief Summary

Evaluate the effect of H.pylori eradication on Gastroesophageal-reflux disease and symptoms improvement

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2024

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

May 27, 2024

Completed
17 days until next milestone

First Posted

Study publicly available on registry

June 13, 2024

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2025

Completed
Last Updated

June 13, 2024

Status Verified

June 1, 2024

Enrollment Period

1 year

First QC Date

May 27, 2024

Last Update Submit

June 9, 2024

Conditions

Keywords

Helicobacter pylori

Outcome Measures

Primary Outcomes (2)

  • Eradication of Helicobacter pylori after triple therapy

    H.pylori eradication will be assessed using the endoscope

    1\2024 to 12\2024

  • Effect of Helicobacter pylori eradication on Gastroesophageal RefIux disease (GERD) syptomes

    Evaluate the effect of H.pylori eradication on Gastroesophageal-reflux disease and correlate with GERD symptoms improvement.

    1\2024 to 12\2024

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All patients diagnosed as GERD clinically and endscopically.

You may qualify if:

  • All patients diagnosed as GERD clinically and endscopically.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Alrajhi Hospital

Asyut, Egypt

RECRUITING

Related Publications (1)

  • Ceylan A, Kirimi E, Tuncer O, Turkdogan K, Ariyuca S, Ceylan N. Prevalence of Helicobacter pylori in children and their family members in a district in Turkey. J Health Popul Nutr. 2007 Dec;25(4):422-7.

    PMID: 18402185BACKGROUND

MeSH Terms

Conditions

Gastroesophageal Reflux

Condition Hierarchy (Ancestors)

Esophageal Motility DisordersDeglutition DisordersEsophageal DiseasesGastrointestinal DiseasesDigestive System Diseases

Study Officials

  • Saad Z Mahmoud, Professor

    Assiut University

    STUDY DIRECTOR

Central Study Contacts

Sara F Abdelhamid elgamal, master

CONTACT

Rasha M Omar, lecturer

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
resident doctor

Study Record Dates

First Submitted

May 27, 2024

First Posted

June 13, 2024

Study Start

January 1, 2024

Primary Completion

December 31, 2024

Study Completion

January 1, 2025

Last Updated

June 13, 2024

Record last verified: 2024-06

Locations